MedTrace Logo

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2023-10-23

No results posted yet for this study

Summary

The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.

The intervention is an educational video and question prompt list (QPL) to promote communication between patients, caregivers, and the oncology team about the risks and benefits of immunotherapy.

Conditions

  • Stage IV Melanoma
  • Advanced Lung Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Unresectable Non-Small Cell Lung Carcinoma
  • Unresectable Stage III Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer Extensive Stage
  • Stage IV Merkel Cell Carcinoma
  • Stage IV Cutaneous Squamous Cell Carcinoma
  • Stage IV Basal Cell Carcinoma
  • Stage IV Breast Cancer
  • Stage IV Colorectal Cancer
  • Stage IV Gastric Cancer
  • Stage IV Esophageal Cancer
  • Stage IV Hepatocellular Cancer
  • Stage IV Renal Cell Carcinoma
  • Stage IV Bladder Cancer
  • Stage IV Head and Neck Squamous Cell Carcinoma
  • Stage IV Cervical Cancer
  • Stage IV Endometrial Cancer
  • Stage IV Mesothelioma
  • Immunotherapy
  • Immune Checkpoint Inhibitors

Interventions

OTHER

Educational Video and QPL List

The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.

OTHER

Usual Care

Surveys

Sponsors & Collaborators

  • Conquer Cancer Foundation

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Laura A Petrillo, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-23
Primary Completion
2023-03-23
Completion
2024-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04670445 on ClinicalTrials.gov